Shire (Pre Election) Pharmaceuticals shares have been hit hard since Clinton's public disapproval of Pharmaceuticals Co.'s prices and profits. Pharmaceuticals shares in general have declined across the board. which is evident in the H1 chart of Shire.
R4 5155.88
R3 4985.27
R2 downward trendline
R1 4634.31
Current 4580.50
S1 4317.47
If Clinton wins I believe we will enter a new lower distribution.
PHARMA
ZTS. Pullback Then DropTrendline support was broken.
Now the price is making a pullback to the broken trend.
Risk trade to sell closer to trendline.
Less risky to sell on break of the first trigger.
Target 38.
More downside for INCYAfter a huge run, Incyte Pharmaceuticals is tired and this flag suggest more downside to come.
Long term bullish on LupinLupin seems to be in a leading diagonal after a big flat correction with C=1.618*A. Hence it could continue to newer highs. Any move below the wave C low would negate the count.
Wockhardt Pharma Breaking Consolidation, Next 865 On hourly chart, the price action breaks out from a consolidation that shall move prices to next resistance level of 865 levels.
Target 865
Stoploss: 830
$ONTX (Onconova Therapeutics) Triple BottomONTX Triple Bottom with increasing volume. I'm looking to be moderately conservative on this buy; the 38.2% Fibonacci level will act as a nice price target for this bullish play.
Viewing this chart, one can see that ONTX has been unable to sustain its gains above the 50% fibline, so you may be able to sell at that point, but as a low float stock anything can happen - it's better to be cautious and take gains in my opinion.
Thank you for viewing my analysis on ONTX! Please like or follow if you like my analyses, or if you have any questions you can contact me anytime.
trend line breakout and RSI divergence in auropharma in 1hr chartrend line breakout and RSI divergence and take Fibonacci retracement 23% support it can go upto 778 1st tgt
Bearish on WockpharmaWockpharma seems to have broken out of it's channel to the downside. Hence a move towards the LTL is possible.
IF there is an upmove (and a reversal) from the channel LTL (as shown by the arrows) then it'd be a great short. In general, up moves could be shorting opportunities.
An up move and a closing inside the channel could be a spoiler for this setup.
Bullish on Mangalam DrugsMangalum Drugs seems to be ending it's downtrend. A close above the UTL could signal the start of the new impulse. It's likely that this impulse would lead it to new highs.
Mangalam Drugs Long updateThe wave 2 correction in Mangalam Drugs seems to have become a bit complex. Now it appears to be at a structural support. Also there is 61% Fib support. So it's likely that the up move could start.
Any move below wave 1 low would negate this setup.
Equity Business RatioProject Manager. OCKT:EERB
EERB
7/08/2016
vlp.eppershh@gmail.com
Growth Rate Charts:PIP: POPS
Equity Business Ratio
7+3=equity return of business;CALL,PUT.BP.IN.ATM.:(ABC)+1 Sell price to bank.
Comprehensible.
Comprehensible input
Possible Lupin countLupin seems to have broken out of it's consolidation after tracing an Elongated Flat correction. In the long term, it seems to be a good long.
LONG LUPINLonger time frame. Decent risk reward ratio of 3x. LUPIN seems to be settling above 200DMA and the next resistance is at 1878. It should reach there in a month or so.
Lupin - Trading Bull Flag Pattern (Buy)As per the observations, it has made a breakout from downward trending line on daily charts and also building a bull flag pattern. I would be expecting a breakout from current levels to reach target of 1850 levels.
Target 1: 1760 Target 2: 1800 Target 3: 1850
Stoploss: 1720
Bullish on Aurobindo PharmaAuro Pharma seems to be starting a healthly uptrend. It's under consolidation now. Going long upon the upper trendline break could be a good idea. The safest entry would be on the break of the topmost trendline.
CIPLA LONGExtremely favourable risk reward trade. Stoploss at 503, just above 200 week moving average. Extremely important level for any stock. It has broken the resistance level of 500 and may soon breach 100 DMA.
First target is 540 and second target is 576.
This trade does derive comfort from the general breakout of pharma sector in India.
$ARNA, $1.50 on the menu... Again!Stock insanely undervalued with Belviq and a great board! Biotechs tend to perform well in bear markets.
I will create a google drive for company models, so that everyone has access.
1.50 is a great price to buy more if you are already in this
GL
www.tradingsignalreviews.com
